Combining Genomics and Imageomics to Predict the Sensitivity of Neoadjuvant Pemetrexed and Cisplatin Chemotherapy in Patients With Lung Adenocarcinoma

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05185544

Enrollment

Registered

2022-01-11

Start date

2022-01-01

Completion date

2024-12-31

Last updated

2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sensitivity

Brief summary

Combining genomics and imageomics to predict the sensitivity of neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma

Interventions

OTHERNeoadjuvant pemetrexed and cisplatin chemotherapy

neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* 1\. Aged between 18 and 75 years; * 2\. Lung adenocarcinoma; * 3\. The patient is able to receive neoadjuvant pemetrexed and cisplatin chemotherapy * 4 .The patient is able to understand and comply with the study and has provided written informed consent.

Exclusion criteria

* 1\. Patients with a history of lung surgery; * 2\. Postoperative pathology showed non-primary lung cancer; * 3\. Patients with a history of other tumors; * 4\. Patients with severe complications (coronary heart disease, valvular heart disease, end-stage renal disease, severe liver cirrhosis); * 5\. Unable to cooperate with the researchers because of dementia or cognitive decline * 6\. Other situations that are not in conformity with the standards and requirements of this trial.

Design outcomes

Primary

Measure	Time frame
Tumor Regression Grade	1-2 Weeks after enrollment (after Surgery)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026